Intravenous dexketoprofen versus paracetamol in non-traumatic musculoskeletal pain in the emergency department: A randomized clinical trial

Demirozogul, Ezgi; Yılmaz, Atakan; Özen, Mert; Turkcuer, Ibrahim; Seyit, Murat; Arikan, Cuneyt

doi:10.1016/j.ajem.2019.01.040

Cited by 10 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Their analysis documented that both drugs significantly reduced nontraumatic musculoskeletal pain in neck, shoulder, back and hip-knee and that these drugs showed no superiority to each other in terms of analgesic efficacy. 12 Consistent the results of this study, the overall findings in our study established that paracetamol and dexketoprofen provided equal pain relief, with no evident superiority to one another.…”

Section: Discussionsupporting

confidence: 90%

Comparative evaluation of intravenous dexketoprofen and paracetamol in the management of pain induced by sore throat

et al. 2021

Self Cite

View full text Add to dashboard Cite

One of the most common reasons for emergency department (ED) admissions is sore throat, which is a prevalent clinical manifestation disturbing patients, especially with upper respiratory tract infections (URTI). Some patients with URTI present to ED with moderate to severe sore throat pain. 1 In such a case, the primary goal of treatment in ED is to alleviate pain immediately and maximising patient comfort with minimum side effects.Relieving sore throat pain in both acute and chronic periods is an indispensable aspect of treatment in URTI. As in other pain types, sore throat has also been treated over years with non-steroidal anti-inflammatory drugs (NSAIDs). Paracetamol and dexketoprofen are among the widely used analgesics administered to cure sore

show abstract

Section: Discussionsupporting

confidence: 90%

Comparative evaluation of intravenous dexketoprofen and paracetamol in the management of pain induced by sore throat

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a prospective, randomized, double-blind, controlled clinical trial Demirozogul E. et al compared the efficacy of paracetamol and DEX in reducing musculoskeletal pain [16]. The pain reported by patients included pain in the shoulder, neck, back, knee and hip.…”

Section: Resultsmentioning

confidence: 99%

“…There was a significant difference between DEX and paracetamol in back pain. Based on the results of the studies, it was found that DEX showed a better analgesic effect in all pain locations compared to paracetamol [16].…”

Section: Resultsmentioning

confidence: 99%

New Studies on Dexketoprofen

Kuczyńska

Pawlak

Nieradko-Iwanicka

2021

Polish Hyperbaric Research

View full text Add to dashboard Cite

Introduction. Dexketoprofen(DEX) belongs to nonsteroidal anti-inflammatory drugs (NSAIDs) and has analgesic, anti-inflammatory, and antipyretic properties. DEX is an enantiomer of ketoprofen (S+) and has a stronger effect than ketoprofen. It is highly effective even after the administration of small doses. The therapy with DEX does not cause serious side effects and is additionally tolerated by the body. Aim. The review aimed to find original scientific publications on DEX in recent years and its therapeutic efficacy, safety, and tolerability. Method. A systematic review of scientific articles published no earlier than 2015 was carried out. Materials from the PubMed, Google Scholar, and Medline Complete databases were used. The literature review was carried out in November 2021. Among the publications found, 28 scientific articles were selected for analysis. Results and discussion. Over the recent years, there have been many publications about DEX. Articles describing new data on DEX in the treatment of pain were analyzed, compared with other drugs and mesotherapy, the latest reports of its combination with tramadol and thiocolchicoside were reviewed, and a new slow release form of DEX and new therapeutic applications of this drug were investigated. After analyzing all the studies, it was found that DEX produced similar or more effective analgesia compared to other drugs and reduced the need for emergency medications. In addition, it was noted that using DEX in combination therapy was far better than taking it alone, and was also found to be effective in raising the epileptic threshold. Mesotherapy achieved higher results in the treatment of pain symptoms compared to DEX. The side effects that appeared as a result of the use of DEX therapy were not life-threatening. Conclusion. The results of the review confirm that DEX is a very good analgesic, which is more potent than paracetamol and diclofenac sodium while having similar effects to dexmedetomidine and lidocaine. DEX in combination with tramadol or thiocolchicoside is more effective than when the two drugs are used alone. Scientists are working on the long-acting DEX and are looking for new applications of the drug in epilepsy and oncology.

show abstract

“…After full analysis, 13 trials were excluded (figure 1). Key data were missing from 25 papers, and the lead authors were contacted to request the information 8–32…”

Section: Methodsmentioning

confidence: 99%

Comparison of intravenous paracetamol (acetaminophen) to intravenously or intramuscularly administered non-steroidal anti-inflammatory drugs (NSAIDs) or opioids for patients presenting with moderate to severe acute pain conditions to the ED: systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

ObjectiveParacetamol, non-steroidal anti-inflammatory drugs (NSAIDs) and opiates/opioids, administered parenterally via intravenous or intramuscular route, are widely used to provide analgesia for patients with moderate to severe pain. This systematic review and meta-analysis evaluated the level of analgesia provided by intravenous paracetamol (IVP) alone compared with NSAIDs (intravenous or intramuscular), or opioids (intravenous) alone in adults attending the ED with acute pain.MethodsTwo authors independently searched PubMed (MEDLINE), Web of Science, Embase (OVID), Cochrane Library, SCOPUS and Google Scholar (3 March 2021–20 May 2022) for randomised trials without any language or date restriction. Clinical trials were evaluated using the Risk of Bias V.2 tool. The primary outcome was mean difference (MD) for pain reduction at 30 min (T30) post analgesia delivery. The secondary outcomes were MD in pain reduction at 60, 90 and 120 min; the need for rescue analgesia; and the occurrence of adverse events (AEs).ResultsTwenty-seven trials (5427 patients) were included in the systematic review and 25 trials (5006 patients) in the meta-analysis. There was no significant difference in pain reduction at T30 between the IVP group and opioids (MD −0.13, 95% CI −1.49 to 1.22) or IVP and NSAIDs (MD −0.27, 95% CI −1.0 to 1.54. There was also no difference at 60 min, IVP group versus opioid group (MD −0.09, 95% CI −2.69 to 2.52) or IVP versus NSAIDs (MD 0.51, 95% CI 0.11 to 0.91). The quality of the evidence using Grading of Recommendations, Assessments, Development and Evaluations methodology was low for MD in pain scores.The need for rescue analgesia at T30 was significantly higher in the IVP group compared with the NSAID group (risk ratio (RR): 1.50, 95% CI 1.23 to 1.83), with no difference found between the IVP group and the opioid group (RR: 1.07, 95% CI 0.67 to 1.70). AEs were 50% lower in the IVP group compared with the opioid group (RR: 0.50, 95% CI 0.40 to 0.62), whereas no difference was observed in the IVP group compared with the NSAID group (RR: 1.30, 95% CI 0.78 to 2.15).ConclusionIn patients presenting to the ED with a diverse range of pain conditions, IVP provides similar levels of pain relief compared with opiates/opioids or NSAIDs at T30 post administration. Patients treated with NSAIDs had lower risk of rescue analgesia, and opioids cause more AEs, suggesting NSAIDs as the first-choice analgesia and IVP as a suitable alternative.PROSPERO registration numberCRD42021240099.

show abstract

Intravenous dexketoprofen versus paracetamol in non-traumatic musculoskeletal pain in the emergency department: A randomized clinical trial

Cited by 10 publications

References 18 publications

Comparative evaluation of intravenous dexketoprofen and paracetamol in the management of pain induced by sore throat

Comparative evaluation of intravenous dexketoprofen and paracetamol in the management of pain induced by sore throat

New Studies on Dexketoprofen

Comparison of intravenous paracetamol (acetaminophen) to intravenously or intramuscularly administered non-steroidal anti-inflammatory drugs (NSAIDs) or opioids for patients presenting with moderate to severe acute pain conditions to the ED: systematic review and meta-analysis

Contact Info

Product

Resources

About